Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims#USA#New_York#Bryan_Jones#AARD_stock#Aardvark_Inc
Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims
Aardvark Therapeutics faces a class action lawsuit over misleading safety claims regarding its drug ARD-101, with major implications for investors.
third-news.com
September 3, 2026 at 2:45 PM
Investigation into Aardvark Therapeutics Securities Class Action Amid Safety Claims#USA#New_York#Bryan_Jones#AARD_stock#Aardvark_Inc
Significant Securities Class Action Filed Against Aardvark Therapeutics, Inc. - Key Dates & Details#United_States#New_York#Aardvark_Therapeutics#AARD#Bryan_Jones
Significant Securities Class Action Filed Against Aardvark Therapeutics, Inc. - Key Dates & Details
Aardvark Therapeutics faces legal action regarding misleading safety claims made by its former COO, Bryan Jones. Investors have until October 13, 2026, to file.
third-news.com
August 19, 2026 at 5:20 PM
Significant Securities Class Action Filed Against Aardvark Therapeutics, Inc. - Key Dates & Details#United_States#New_York#Aardvark_Therapeutics#AARD#Bryan_Jones